• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee

 

 
Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
Morning Session
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information, Tivozanib Capsules, for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF – 143KB)
 
 
AVEO Pharmaceuticals, Inc.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
AVEO Briefing Information, Tivozanib Capsules, for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF – 990KB)
 
Afternoon Session
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information, Melblez Kit, for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF – 219KB)
 
 
Delcath Systems, Inc.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Delcath Briefing Information, Melblez Kit, for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF – 782KB)